Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Biorxiv : the Preprint Server for Biology|November 22, 2024
Selective Enhancement of the Interneuron Network and Gamma-Band Power via GluN2C/GluN2D NMDA Receptor PotentiationChad R Camp, Tue G Banke, Hao Xing, et al.
Journal of Medicinal Chemistry|December 22, 2009
Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic painPaul C Fritch, Grant McNaughton-Smith, George S Amato, et al.
The Journal of Physiology|June 25, 2025
Selective enhancement of the interneuron network and gamma-band power via GluN2C/GluN2D NMDA receptor potentiationChad R Camp, Tue G Banke, Hao Xing, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 11, 2007
Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigsAnindya Bhattacharya, Brian P Scott, Nadia Nasser, et al.
The Journal of Biological Chemistry|December 25, 2019
Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNav1.7Robert A Neff, Mack Flinspach, Alan Gibbs, et al.
The Journal of Physiology|October 7, 2025
Enhancement of hippocampal interneuron excitability by NMDA receptor positive allosteric modulationHao Xing, Tue G Banke, Lu Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|August 10, 2011
Discovery of a novel series of selective HCN1 blockersKelly J McClure, Michael Maher, Nancy Wu, et al.
British Journal of Pharmacology|July 30, 2013
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567Anindya Bhattacharya, Qi Wang, Hong Ao, et al.
The Journal of Biological Chemistry|June 14, 2013
Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin huwentoxin-IV (μ-TRTX-Hh2a)Natali A Minassian, Alan Gibbs, Amy Y Shih, et al.
Bioorganic & Medicinal Chemistry Letters|September 6, 2016
The discovery and preclinical characterization of 6-chloro-N-(2-(4,4-difluoropiperidin-1-yl)-2-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinoline-5-carboxamide based P2X7 antagonistsJason C Rech, Anindya Bhattacharya, Bryan J Branstetter, et al.
Pageof 7